vs
Side-by-side financial comparison of QuidelOrtho Corp (QDEL) and Westrock Coffee Co (WEST). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($619.8M vs $339.5M, roughly 1.8× Westrock Coffee Co). Westrock Coffee Co runs the higher net margin — -6.6% vs -14.8%, a 8.2% gap on every dollar of revenue. On growth, Westrock Coffee Co posted the faster year-over-year revenue change (48.3% vs -10.5%). Over the past eight quarters, Westrock Coffee Co's revenue compounded faster (32.8% CAGR vs -6.6%).
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
Westrock Coffee Co is a global integrated coffee, tea and functional beverage solutions provider. It sources, roasts, manufactures and distributes coffee products, ready-to-drink beverages and custom formulations for retail, foodservice and commercial clients across North America and other key markets.
QDEL vs WEST — Head-to-Head
Income Statement — Q1 FY2027 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $619.8M | $339.5M |
| Net Profit | $-91.8M | $-22.6M |
| Gross Margin | — | 11.5% |
| Operating Margin | — | -2.6% |
| Net Margin | -14.8% | -6.6% |
| Revenue YoY | -10.5% | 48.3% |
| Net Profit YoY | — | 8.3% |
| EPS (diluted) | $-1.35 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $619.8M | — | ||
| Q4 25 | — | $339.5M | ||
| Q3 25 | $699.9M | $354.8M | ||
| Q2 25 | $613.9M | $280.9M | ||
| Q1 25 | $692.8M | $213.8M | ||
| Q4 24 | $707.8M | $229.0M | ||
| Q3 24 | $727.1M | $220.9M | ||
| Q2 24 | $637.0M | $208.4M |
| Q1 26 | $-91.8M | — | ||
| Q4 25 | — | $-22.6M | ||
| Q3 25 | $-733.0M | $-19.1M | ||
| Q2 25 | $-255.4M | $-21.6M | ||
| Q1 25 | $-12.7M | $-27.2M | ||
| Q4 24 | $-178.4M | $-24.6M | ||
| Q3 24 | $-19.9M | $-14.3M | ||
| Q2 24 | $-147.7M | $-17.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | 11.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 14.7% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 16.8% | ||
| Q2 24 | — | 19.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | -2.6% | ||
| Q3 25 | -100.7% | -2.4% | ||
| Q2 25 | -29.4% | -5.3% | ||
| Q1 25 | 4.7% | -6.1% | ||
| Q4 24 | -14.2% | -4.3% | ||
| Q3 24 | 2.1% | -5.8% | ||
| Q2 24 | -18.4% | -7.9% |
| Q1 26 | -14.8% | — | ||
| Q4 25 | — | -6.6% | ||
| Q3 25 | -104.7% | -5.4% | ||
| Q2 25 | -41.6% | -7.7% | ||
| Q1 25 | -1.8% | -12.7% | ||
| Q4 24 | -25.2% | -10.7% | ||
| Q3 24 | -2.7% | -6.5% | ||
| Q2 24 | -23.2% | -8.5% |
| Q1 26 | $-1.35 | — | ||
| Q4 25 | — | $-0.22 | ||
| Q3 25 | $-10.78 | $-0.20 | ||
| Q2 25 | $-3.77 | $-0.23 | ||
| Q1 25 | $-0.19 | $-0.29 | ||
| Q4 24 | $-2.54 | $-0.26 | ||
| Q3 24 | $-0.30 | $-0.16 | ||
| Q2 24 | $-2.20 | $-0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $140.4M | $49.9M |
| Total DebtLower is stronger | $2.5B | $444.1M |
| Stockholders' EquityBook value | $1.9B | $-1.9M |
| Total Assets | $5.6B | $1.2B |
| Debt / EquityLower = less leverage | 1.33× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $140.4M | — | ||
| Q4 25 | — | $49.9M | ||
| Q3 25 | $98.1M | $34.0M | ||
| Q2 25 | $151.7M | $44.0M | ||
| Q1 25 | $127.1M | $33.1M | ||
| Q4 24 | $98.3M | $26.2M | ||
| Q3 24 | $143.7M | $22.4M | ||
| Q2 24 | $107.0M | $24.3M |
| Q1 26 | $2.5B | — | ||
| Q4 25 | — | $444.1M | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | $393.1M | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — |
| Q1 26 | $1.9B | — | ||
| Q4 25 | — | $-1.9M | ||
| Q3 25 | $2.0B | $11.4M | ||
| Q2 25 | $2.8B | $18.2M | ||
| Q1 25 | $3.0B | $71.4M | ||
| Q4 24 | $3.0B | $97.5M | ||
| Q3 24 | $3.2B | $110.3M | ||
| Q2 24 | $3.2B | $81.5M |
| Q1 26 | $5.6B | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | $5.7B | $1.2B | ||
| Q2 25 | $6.4B | $1.2B | ||
| Q1 25 | $6.5B | $1.1B | ||
| Q4 24 | $6.4B | $1.1B | ||
| Q3 24 | $6.8B | $1.1B | ||
| Q2 24 | $6.7B | $1.1B |
| Q1 26 | 1.33× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | 4.03× | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $36.7M |
| Free Cash FlowOCF − Capex | — | $27.8M |
| FCF MarginFCF / Revenue | — | 8.2% |
| Capex IntensityCapex / Revenue | — | 2.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-107.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $36.7M | ||
| Q3 25 | $-45.5M | $-26.6M | ||
| Q2 25 | $-46.8M | $-7.0M | ||
| Q1 25 | $65.6M | $-22.1M | ||
| Q4 24 | $63.7M | $2.8M | ||
| Q3 24 | $117.9M | $-332.0K | ||
| Q2 24 | $-97.9M | $-23.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $27.8M | ||
| Q3 25 | $-94.7M | $-44.7M | ||
| Q2 25 | $-84.3M | $-27.5M | ||
| Q1 25 | $9.4M | $-63.4M | ||
| Q4 24 | $16.5M | $-15.4M | ||
| Q3 24 | $71.4M | $-36.7M | ||
| Q2 24 | $-133.2M | $-59.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 8.2% | ||
| Q3 25 | -13.5% | -12.6% | ||
| Q2 25 | -13.7% | -9.8% | ||
| Q1 25 | 1.4% | -29.7% | ||
| Q4 24 | 2.3% | -6.7% | ||
| Q3 24 | 9.8% | -16.6% | ||
| Q2 24 | -20.9% | -28.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.6% | ||
| Q3 25 | 7.0% | 5.1% | ||
| Q2 25 | 6.1% | 7.3% | ||
| Q1 25 | 8.1% | 19.3% | ||
| Q4 24 | 6.7% | 7.9% | ||
| Q3 24 | 6.4% | 16.5% | ||
| Q2 24 | 5.5% | 17.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
WEST
| Coffee And Tea | $202.6M | 60% |
| Flavors Extracts And Ingredients | $69.6M | 21% |
| Sustainable Sourcing And Traceability Segments | $66.9M | 20% |
